Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 1:5:1441601.
doi: 10.3389/froh.2024.1441601. eCollection 2024.

Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review

Rodolfo Mauceri  1   2 , Sonia Arduini  3 , Martina Coppini  1   2   4 , Monica Bazzano  2 , Isabel Trujillo  3 , Giuseppina Campisi  1
Affiliations

Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review

Rodolfo Mauceri et al. Front Oral Health. .

Abstract

Introduction: Medication-related osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to BMA and AA therapies, causing the progressive destruction and death of bone. To date, oral health preventive measures remain the most effective strategy to reduce MRONJ incidence, and, in this sense, the major goal is to diagnose, treat, and eradicate any oral diseases that could compromise oral health. The present systematic review aims to investigate the awareness of MRONJ among patients assuming BMAs.

Methods: A systematic literature search was performed, selecting studies that concern the awareness of patients of the risk of MRONJ.

Results: Six studies were included in this review. In total, 483 patients were evaluated. Of the 483 included patients, 391 were not aware of the possibility of MRONJ onset (391/483, 81%) and 92 were aware of it (92/483, 19%).

Discussion: The problem of patient's lack of awareness with respect to MRONJ risk presents different layers of complexity ("what?", "who?", "where?", "when?" and "why?"). Among its causal factors, there are an inadequate level of communication with patients and the lack of collaboration between healthcare professionals, which is related to an individualistic view of liability and deontological duties. MRONJ is a drug adverse reaction that can greatly affect the quality of life of patients if not promptly diagnosed and treated. Therefore, patients must be fully aware of the risks of adverse and the importance of preventive measures, which imply effective and exhaustive communication by each member of the multidisciplinary team. Effective teamwork and collaborative care should be promoted to positively impact patients' awareness.

Keywords: MRONJ; ONJ; awareness; bisphosphonate-associated osteonecrosis of the jaw; knowledge; medication-related osteonecrosis of the jaw; osteonecrosis of the jaw; patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
PRISMA 2020 flow diagram.
See this image and copyright information in PMC

References

    1. Bedogni A, Mauceri R, Fusco V, Bertoldo F, Bettini G, Di Fede O, et al. Italian Position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ). Oral Dis. (2024). 10.1111/odi.14887. [Epub ahead of print]. - DOI - PubMed
    1. Mauceri R, Coppini M, Perez-Sayans M, Toro C, Vitagliano R, Colella G, et al. Challenges in the diagnosis of oral squamous cell carcinoma mimicking medication-related osteonecrosis of the jaws: a multi-hospital-based case series. Oral Oncol. (2024) 151:106689. 10.1016/j.oraloncology.2024.106689 - DOI - PubMed
    1. Fusco V, Campisi G, Bedogni A. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ). Support Care Cancer. (2022) 30(9):7047–51. 10.1007/s00520-022-06982-y - DOI - PMC - PubMed
    1. Srivastava A, Nogueras Gonzalez GM, Geng Y, Won AM, Myers J, Li Y, et al. Medication-related osteonecrosis of the jaw in patients treated concurrently with antiresorptive and antiangiogenic agents: systematic review and meta-analysis. J Immunother Precis Oncol. (2021) 4(4):196–207. 10.36401/JIPO-21-14 - DOI - PMC - PubMed
    1. Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent. (2021) 7(1):47. 10.1186/s40729-021-00323-0 - DOI - PMC - PubMed

Publication types

LinkOut - more resources